Qiyu Li
Bern, BE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001-2020): A Meta-Analysis of Pivotal Randomised Controlled Trials.
Journal: The Lancet regional health. Europe
Published: January 23, 2026
Navigating the complexity: reflections on the development of perioperative cancer treatments.
Journal: The Lancet. Oncology
Published: April 06, 2025
Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.
Journal: The Lancet. Oncology
Published: December 22, 2023
Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 21, 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA oncology
Published: August 10, 2023
A long-term retrospective observational study at a medium-sized medical oncology service in Switzerland: comparison of overall survival with a national cohort and adherence to treatment guidelines.
Journal: Swiss medical weekly
Published: July 17, 2023
A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.
Journal: Clinical and translational science
Published: March 31, 2023
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Journal: Scientific reports
Published: October 04, 2022
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
Journal: Journal of geriatric oncology
Published: February 02, 2022
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.
Journal: Endocrine oncology (Bristol, England)
Published: January 23, 2022
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 22, 2021
Last Updated: 09/26/2026